|
🐜
|
miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic Blasts
25 auth.
A. Eiring,
Jason G. Harb,
P. Neviani,
C. Garton,
J. Oaks,
R. Spizzo,
Shujun Liu,
S. Schwind,
R. Santhanam,
Christopher J. Hickey,
H. Becker,
J. Chandler,
R. Andino,
J. Cortes,
P. Hokland,
...
C. Huettner,
R. Bhatia,
D. Roy,
S. Liebhaber,
M. Caligiuri,
G. Marcucci,
R. Garzon,
C. Croce,
G. Calin,
D. Perrotti
|
9 |
2010 |
9
🐜
|
|
🐜
|
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
29 auth.
Shaji K. Kumar,
N. Callander,
M. Alsina,
D. Atanackovic,
J. Biermann,
J. Chandler,
C. Costello,
M. Faiman,
H. Fung,
C. Gasparetto,
Kelly Godby,
C. Hofmeister,
L. Holmberg,
S. Holstein,
C. Huff,
...
A. Kassim,
M. Liedtke,
T. Martin,
J. Omel,
N. Raje,
F. Reu,
S. Singhal,
G. Somlo,
K. Stockerl-Goldstein,
S. Treon,
D. Weber,
J. Yahalom,
Dorothy Shead,
Rashmi Kumar
|
7 |
2017 |
7
🐜
|
|
🐜
|
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First‐Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)
12 auth.
D. Spigel,
C. Reynolds,
D. Waterhouse,
E. Garon,
J. Chandler,
S. Babu,
...
P. Thurmes,
A. Spira,
R. Jotte,
Jin Zhu,
Wen-hong Lin,
G. Blumenschein
|
7 |
2018 |
7
🐜
|
|
🐜
|
Safety, Efficacy, and Patient-reported Health-related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged ≥70 Years or with Poor Performance Status (CheckMate 153).
21 auth.
D. Spigel,
M. Mccleod,
R. Jotte,
L. Einhorn,
L. Horn,
D. Waterhouse,
B. Creelan,
S. Babu,
N. Leighl,
J. Chandler,
...
F. Couture,
G. Keogh,
G. Goss,
D. Daniel,
E. Garon,
L. Schwartzberg,
R. Sen,
B. Korytowsky,
A. Li,
Nivedita Aanur,
M. Hussein
|
7 |
2019 |
7
🐜
|
|
🐜
|
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.
29 auth.
Shaji K. Kumar,
N. Callander,
K. Adekola,
L. Anderson,
M. Baljevic,
E. Campagnaro,
J. Castillo,
J. Chandler,
C. Costello,
Y. Efebera,
M. Faiman,
Alfred L. Garfall,
Kelly Godby,
J. Hillengass,
L. Holmberg,
...
M. Htut,
C. Huff,
Yubin Kang,
M. Hultcrantz,
Sarah M. Larson,
M. Liedtke,
T. Martin,
J. Omel,
K. Shain,
D. Sborov,
K. Stockerl-Goldstein,
D. Weber,
J. Keller,
Rashmi Kumar
|
7 |
2020 |
7
🐜
|
|
🐜
|
Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation.
26 auth.
A. Mishra,
Shujun Liu,
G. Sams,
Douglas P. Curphey,
R. Santhanam,
L. Rush,
D. Schaefer,
Lauren G. Falkenberg,
Laura A. Sullivan,
Laura Jaroncyk,
Xiaojuan Yang,
H. Fisk,
Lai-Chu Wu,
Christopher J. Hickey,
J. Chandler,
...
Yue-zhong Wu,
N. Heerema,
K. Chan,
D. Perrotti,
Jianying Zhang,
P. Porcu,
F. Racke,
R. Garzon,
Robert J. Lee,
G. Marcucci,
M. Caligiuri
|
7 |
2012 |
7
🐜
|
|
🐜
|
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153
23 auth.
D. Waterhouse,
E. Garon,
J. Chandler,
M. Mccleod,
M. Hussein,
R. Jotte,
L. Horn,
D. Daniel,
G. Keogh,
B. Creelan,
...
L. Einhorn,
J. Baker,
S. Kasbari,
P. Nikolinakos,
S. Babu,
F. Couture,
N. Leighl,
C. Reynolds,
G. Blumenschein,
V. Gunuganti,
A. Li,
Nivedita Aanur,
D. Spigel
|
7 |
2020 |
7
🐜
|
|
🐜
|
NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020.
31 auth.
Shaji K. Kumar,
N. Callander,
J. Hillengass,
M. Liedtke,
M. Baljevic,
E. Campagnaro,
J. Castillo,
J. Chandler,
R. Cornell,
C. Costello,
Y. Efebera,
M. Faiman,
Alfred L. Garfall,
Kelly Godby,
L. Holmberg,
...
M. Htut,
C. Huff,
Yubin Kang,
O. Landgren,
E. Malek,
T. Martin,
J. Omel,
N. Raje,
D. Sborov,
S. Singhal,
K. Stockerl-Goldstein,
C. Tan,
D. Weber,
Alyse Johnson-Chilla,
J. Keller,
Rashmi Kumar
|
7 |
2019 |
7
🐜
|
|
🐬
|
Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.
Il-kyoo Park,
A. Mishra,
J. Chandler,
S. Whitman,
G. Marcucci,
M. Caligiuri
|
6 |
2013 |
6
🐬
|
|
🐜
|
Dose escalation of lenalidomide in relapsed or refractory acute leukemias.
19 auth.
W. Blum,
R. Klisovic,
H. Becker,
Xiaoxia Yang,
Darlene M. Rozewski,
M. Phelps,
R. Garzon,
A. Walker,
J. Chandler,
S. Whitman,
...
John Curfman,
Shujun Liu,
L. Schaaf,
J. Mickle,
C. Kefauver,
S. Devine,
M. Grever,
G. Marcucci,
J. Byrd
|
6 |
2010 |
6
🐜
|
